In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]
In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]
In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]
In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]
In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend – and why their rhetoric rings hollow when measured against their companies’ track record. […]
As bipartisan momentum to hold Big Pharma accountable and take action on out-of-control drug prices continues to build, the U.S. Senate Committee on Finance is scheduled to question the executives of seven major pharmaceutical manufacturers on February 26, 2019. In advance of the hearing, the second held by the committee on drug pricing this year, […]
On Tuesday, the U.S. House Oversight and Reform and Senate Finance Committees held their first hearings on drug pricing. The fact that the first hearings held in these committees were about skyrocketing drug prices sent a clear message to Big Pharma that Congress is ready to hold them accountable for their price-gouging tactics. Check out […]
Drug Companies Have Been Warned: House & Senate Chairmen & Ranking Members Pledge To Work Together To Hold Big Pharma Accountable U.S. Senate Chairman Of The Committee On Finance Chuck Grassley: “You will hear many numbers describing the costs of prescription drugs. Those numbers are impressive, but the stories I have heard from patients, doctors, […]
The jig is up – a new report showsthat “the skyrocketing cost of many prescription drugs in the U.S. can be blamed primarily on price increases, not expensive new therapies or improvements in existing medications as drug companies frequently claim.” The new research, published in Health Affairs, shows that drugs are increasing at a rate faster than […]
Right on cue, dozens of pharmaceutical companies rang in the new year by increasing hundreds of drug prices by up to 15 times the rate of inflation – despite the fact that their profits continue to far exceed spending on research and development. In just one week: Allergan increased the price of two dozen drugs […]